ATLANTA -- Routine use of the Impella CP microaxial flow pump significantly improved survival in patients with infarct-related cardiogenic shock, the randomized DanGer Shock trial showed.

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

Recently, however, the DanGer Shock trial delivered a decisively positive result for Impella in highly selected patients with STEMI complicated by cardiogenic shock. On the strength of that trial, the ...

Patients with severe heart failure or cardiogenic shock often require assistance from MCS devices such as venoarterial ...

Second Heart Assist today announced data from a study highlighting the performance of its Whisper device against a competitive heart pump.

While this study utilized the Johnson & Johnson (Abiomed) Impella CP® device ... congestion (cardio-renal syndrome (CRS), and/or cardiogenic shock (CS), and those in need of prophylactic ...

As Healio previously reported, routine use of a microaxial flow pump (Impella CP ... care alone for patients with STEMI and cardiogenic shock. The class IIA guideline recommendation is specific ...